Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12)

Trial Profile

A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12)

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Registrational; Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 26 Nov 2018 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2018 Primary endpoint (IGA severity of disease) has been met, according to the Foamix media release.
    • 07 Nov 2018 Primary endpoint (Inflammatory Lesion Counts) has been met, according to the Foamix media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top